Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)

NCT00517920 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Hepatocellular Carcinoma

Interventions

DRUG: ABT-869

Sponsor

AbbVie (prior sponsor, Abbott)

Collaborators

[object Object]